Praxair Acquires NOxBOX Ltd, a Leading Developer of Inhaled Nitric Oxide Delivery and Monitoring Systems
March 02, 2016
DANBURY, Conn., March 2, 2016 – Praxair, Inc. (NYSE: PX) has acquired NOxBOX Ltd, a company that specializes in the manufacture of inhaled gas delivery and monitoring instruments for the medical market, from U.K.-based Bedfont Scientific Limited, an existing Praxair supplier. Financial terms of the transaction were not disclosed.
NOxBOX Ltd, which will remain headquartered in the U.K., provides a range of medical devices for in-hospital use as currently authorized by local regulation. One such device, the NOxBOXi™ delivery system, which is currently sold in many countries, provides intelligent nitric oxide delivery with precise real-time monitoring of nitric oxide, nitrogen dioxide and oxygen through a touch screen with step-by-step guided interface to enable ease of use.
“We are very pleased to have acquired this comprehensive means of delivering and monitoring nitric oxide for patients in need of inhaled nitric oxide therapy,” said Scott Telesz, executive vice president, Praxair. “The acquisition of this product line is part of our long-term strategy to further broaden our offerings to hospitals and deliver the latest in respiratory healthcare technology to our customers around the world.”
Praxair, Inc., a Fortune 250 company with 2015 sales of $11 billion, is the largest industrial gases company in North and South America and one of the largest worldwide. The company produces, sells and distributes atmospheric, process and specialty gases, and high-performance surface coatings. Praxair products, services and technologies are making our planet more productive by bringing efficiency and environmental benefits to a wide variety of industries, including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing, primary metals and many others. More information about Praxair, Inc. is available at www.praxair.com.